These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. The potential influence of 5-aminosalicylic acid on the induction of myelotoxicity during thiopurine therapy in inflammatory bowel disease patients. Gao X; Zhang FB; Ding L; Liu H; Wang XD; Chen BL; Bi HC; Xiao YL; Zhao LZ; Chen MH; Huang M; Hu PJ Eur J Gastroenterol Hepatol; 2012 Aug; 24(8):958-64. PubMed ID: 22664938 [TBL] [Abstract][Full Text] [Related]
10. Inflammatory bowel disease: adherence to immunomodulators in a biological therapy era. Campos S; Portela F; Sousa P; Sofia C Eur J Gastroenterol Hepatol; 2016 Nov; 28(11):1313-9. PubMed ID: 27501126 [TBL] [Abstract][Full Text] [Related]
11. Prediction of Thiopurine Metabolite Levels Based on Haematological and Biochemical Parameters. Hradsky O; Potuznikova K; Siroka J; Lerchova T; Urbanek L; Mihal V; Spenerova M; Velganova-Veghova M; Karaskova E; Bronsky J J Pediatr Gastroenterol Nutr; 2019 Oct; 69(4):e105-e110. PubMed ID: 31568041 [TBL] [Abstract][Full Text] [Related]
13. Identifying youth nonadherence in clinical settings: data-based recommendations for children and adolescents with inflammatory bowel disease. Greenley RN; Kunz JH; Biank V; Martinez A; Miranda A; Noe J; Telega G; Tipnis NA; Werlin S; Stephens MC Inflamm Bowel Dis; 2012 Jul; 18(7):1254-9. PubMed ID: 22689633 [TBL] [Abstract][Full Text] [Related]
14. Risk Factors for Medication Nonadherence to Self-Injectable Biologic Therapy in Adult Patients With Inflammatory Bowel Disease. Shah NB; Haydek J; Slaughter J; Ashton JR; Zuckerman AD; Wong R; Raffa F; Garrett A; Duley C; Annis K; Wagnon J; Gaines L; Dalal R; Scoville E; Beaulieu DB; Schwartz D; Horst SN Inflamm Bowel Dis; 2020 Jan; 26(2):314-320. PubMed ID: 31671188 [TBL] [Abstract][Full Text] [Related]
15. Clinical Predictors of Future Nonadherence in Inflammatory Bowel Disease. Severs M; Mangen MJ; Fidder HH; van der Valk ME; van der Have M; van Bodegraven AA; Clemens CHM; Dijkstra G; Jansen JM; de Jong DJ; Mahmmod N; van de Meeberg PC; van der Meulen-de Jong AE; Pierik M; Ponsioen CY; Romberg-Camps MJL; Siersema PD; Jharap B; van der Woude JC; Zuithoff NPA; Oldenburg B Inflamm Bowel Dis; 2017 Sep; 23(9):1568-1576. PubMed ID: 28700534 [TBL] [Abstract][Full Text] [Related]
17. The Frequency of Clinic Visits Was Not Associated with Medication Adherence or Outcome in Children with Inflammatory Bowel Diseases. Kluthe C; Tsui J; Spady D; Carroll M; Wine E; Huynh HQ Can J Gastroenterol Hepatol; 2018; 2018():4687041. PubMed ID: 29682493 [TBL] [Abstract][Full Text] [Related]
18. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Dubinsky MC; Yang H; Hassard PV; Seidman EG; Kam LY; Abreu MT; Targan SR; Vasiliauskas EA Gastroenterology; 2002 Apr; 122(4):904-15. PubMed ID: 11910342 [TBL] [Abstract][Full Text] [Related]
19. Subjective Versus Objective Measures of Medication Adherence in Adolescents/Young Adults with Attention-Deficit Hyperactivity Disorder. Schaefer MR; Wagoner ST; Young ME; Rawlinson AR; Kavookjian J; Shapiro SK; Gray WN J Dev Behav Pediatr; 2019 Jan; 40(1):54-59. PubMed ID: 30001262 [TBL] [Abstract][Full Text] [Related]
20. Current practice and perception of screening for medication adherence in inflammatory bowel disease. Trindade AJ; Morisky DE; Ehrlich AC; Tinsley A; Ullman TA J Clin Gastroenterol; 2011; 45(10):878-82. PubMed ID: 21555953 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]